Noelia Ortiz, MME, CSSGB, CQA, CSQE

Audits rarely fail because of one big issue. They fail because of repeatable patterns. This short video breaks down what FDA inspectors see most often, including: ✅ CAPA documentation gaps ✅ Incomplete training records ✅ Traceability issues between design & production If your risk files or QMS processes touch any of these areas… it’s worth a 3-minute watch. #FDA #AuditReady #QualitySystems #ISO13485 #ISO14971 #CAPA #MedTech #RegulatoryAffairs #Qualira https://zurl.co/qRzlR

4

Most Quality Systems Are Structurally Reactive Most regulated organizations believe they are inspection-ready. Many are simply inspection-prepared. There is a difference. Preparation focuses on documentation. Readiness focuses on system design. Reactive quality systems share common patterns: • Deviations surface late • CAPA cycles repeat • Audit observations cluster • Compliance consumes operational capacity Inspection resilience comes from architecture, not activity. Effective quality governance embeds: Upstream risk detection Cross-functional accountability Leading indicator visibility Quality is not a control department. It is an enterprise risk containment system. Organizations that treat it as such stabilize operations and reduce audit exposure long before regulators arrive. The question is not whether your organization can pass an audit. It’s whether your systems are designed to prevent one from ever becoming a risk event.

3

🧭 The FDA’s transition from QSR to QMSR, aligning with ISO 13485, is more than a regulatory update — it’s a mindset shift. ⚙️ Quality is no longer a checkbox at the end of development. It’s becoming the operating system for how medtech and biotech teams build, scale, and innovate. 📈 Teams that treat this transition as a strategic advantage — not just a compliance exercise — will scale smarter, de-risk earlier, and build trust faster. #FDA #QMSR #ISO13485 #Medtech #Biotech

4

*** Don’t migrate today’s problems into tomorrow’s QMS *** Data quality, integration gaps, and legacy customizations are some of the biggest reasons QMS solutions cause compliance issues and violations. Before you select a new platform, be sure you have a strategy to: - Understand your current use cases and needs - Analyze, cleanse and enrich data - Map integrations - Solve current and future challenges You’re not alone, and fme can help. We have 25 years of life sciences experience and a proven methodology to help you select the right platform for your processes and environment. 👉 Learn more below! #Quality #migration #LifeSciences #SoftwareSelection https://fme.smh.re/CYq

4

18 months of FDA Warning Letters. Same 4 failures. Every time. → CAPA systems that don't catch root causes → SOPs nobody follows → Changes rolling out without validation → Data integrity gaps (FDA's new favorite) Your 2025 reality check: FDA already knows what they'll find at your next inspection. Do you? These aren't random citations. They're predictable patterns hitting companies still treating QMS as a checkbox exercise instead of operational advantage. Planning 2025? Fix these gaps now or explain them to FDA later. Let's talk before your inspection becomes a case study. #MedTech #FDA #QualityManagement

10